Login to Your Account

Xenon, Teva forging ahead in PHN after OA trial falls short

By Jennifer Boggs
Staff Writer

Wednesday, July 1, 2015

A phase IIb failure of sodium channel Nav1.7 inhibitor TV-45070 in osteoarthritis (OA) of the knee should have no readthrough to an ongoing phase IIb study of the topically applied small molecule in postherpetic neuralgia (PHN), executives of Xenon Pharmaceuticals Inc. assured investors Wednesday morning, citing distinct pain mechanisms between OA and neuropathic pain indications.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription